Lee's Pharmaceutical Holdings Limited (00950.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.8x

Market Cap

HKD 724.27M

MomentumView details →

1D Return

−2.38%

YTD Return

−19.08%

RSI (14)

54.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

2.8x

Market Cap

HKD 724.27M

RSI (14)

54.8

MomentumView details →

1D Return

−2.38%

YTD Return

−19.08%

ProfitabilityView details →

Gross Margin

52.89%

Net Margin

8.14%

EBITDA Margin

8.08%

ROE (TTM)

7.22%

ROA (TTM)

4.40%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

+32.92%

EPS YoY

+59.78%

FCF YoY

+56.60%

Revenue CAGR 3Y

+5.21%

EPS CAGR 3Y

+22.47%

EBITDA YoY

−42.14%

EarningsView details →

EPS (Actual)

HKD 0.16

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.12x

Current Ratio

1.06x

Quick Ratio

0.69x

Div Yield

3.66%

Div Rate

HKD 0.05

Div Growth 1Y

−51.06%

Financials snapshotView financials →

Revenue (TTM)

1.89B

Net Income (TTM)

153.36M

Op. CF (TTM)

552.30M

Next earningsMar 30, 2027 →

Latest newsMore news →

Lee's Pharmaceutical Holdings declared an interim dividend of HK$0.035 per share for the six months ended June 2026, up 59.1% from HK$0.022 per share in the prior-year period.4d ago

Lee's Pharmaceutical Holdings issued a profit alert, expecting its interim net profit attributable to shareholders to rise 26-41% year-on-year to HK$85-95 million, driven by revenue growth and improved gross margin.9d ago

Similar companies

Ironwood Pharmaceuticals, Inc.IRWD Collegium Pharmaceutical, Inc.COLL Aquestive Therapeutics, Inc.AQST Pak Fah Yeow International Limited00239.HK Evotec SEEVO Esperion Therapeutics, Inc.ESPR Find similar companies →

Latest newsMore news →

Lee's Pharmaceutical Holdings declared an interim dividend of HK$0.035 per share for the six months ended June 2026, up 59.1% from HK$0.022 per share in the prior-year period.4d ago Lee's Pharmaceutical Holdings issued a profit alert, expecting its interim net profit attributable to shareholders to rise 26-41% year-on-year to HK$85-95 million, driven by revenue growth and improved gross margin.9d ago Lee's Pharmaceutical's new drug clinical trial application for its proprietary ADC project ZK2401 was accepted by the Center for Drug Evaluation of China's National Medical Products Administration on 2026-07-29.36d ago